Design and In Silico and In Vitro Evaluations of a Novel Nicotinamide Derivative as a VEGFR-2 Inhibitor

Figure 17

Cytotoxic activities of compound 10 against HepG2 (a) and MCF-7 (b), comparing sorafenib against HepG2 (c) and MCF-7 (d).

(a)

(b)

(c)

(d)